Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Food and Drug Administration holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data indicates 1 pending office action for the organization. This workload is distributed across 1 distinct examiner and 1 distinct art unit. The prosecution activity is currently concentrated in a single administrative area, reflecting a specific focus for the organization's current intellectual property efforts. This centralized structure within the biotechnology and pharmaceutical domain allows for a more focused management of the organization's pending matters.
DACE DENITO, ALEXANDRA GERALDINE is the busiest examiner for the portfolio. This examiner is currently handling 1 busiest examiner pending office action. With this individual serving as the sole point of contact for the organization's active patent matters, strategy should be tailored to the specific practices of this examiner. The outcome of the organization's current patenting activity is dependent on the review conducted by this specific examiner and the standards of the associated art unit. By concentrating on the specific tendencies of this examiner, the organization can develop a more effective strategy for addressing the requirements of the single pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17270501 | Methods to Control Viral Infection in Mammalian Cells | DACE DENITO, ALEXANDRA GERALDINE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17270501 | Methods to Control Viral Infection in Mammalian Cells | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Final Rejection | — | Pending | Feb 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Food and Drug Administration has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexandra Geraldine Dace Denito has the most, with 1 of The Food and Drug Administration's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
